Of course, considering Neuren's situation / pipeline / results to date, the company will base a fair T/O price on a DCF valuation. Isn't that a no brainer?
Whether any other side would come to the party is another matter, especially if there is a huge discrepancy between DCF & SP - which would almost certainly be the case.
The Whens and Whys of Top Biotech M&A Deals, page-33
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.25 |
Change
-0.100(0.81%) |
Mkt cap ! $1.565B | |||
| Open | High | Low | Value | Volume |
| $12.20 | $12.25 | $12.02 | $3.677M | 302.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1579 | $12.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.26 | 1199 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |